Table 1.
Fold changes in immunomodulators in limited- and multiple-antibody patientsa
| Immunomodulator | Fold change |
||
|---|---|---|---|
| Multiple-antibody patients vs baseline | Limited-antibody patients vs baseline | Multiple- vs limited-antibody patients | |
| MIG (CXCL9) | 3.7 | 6.0 | (2.4) |
| VEGF | 2.5 | 3.9 | (1.4) |
| IP-10 (CXCL10) | 4.0 | 9.4 | (5.4) |
| IL-2 | 3.1 | 3.9 | (0.8) |
| PDGF-BB | 2.2 | 2.4 | (0.1) |
| IL-6 | 1.8 | 4.6 | (2.8) |
| HGF | 1.9 | 2.8 | (0.9) |
| IL-16 | (1.7) | (3.8) | 2.1 |
| IL-12(p70) | 1.4 | 2.2 | (0.7) |
| FGF basic | 1.5 | 2.6 | (1.1) |
| MIP-1α (CCL3) | 1.3 | 2.2 | (0.9) |
| G-CSF | 0.0 | 2.4 | (2.4) |
| IL-17 | 1.3 | 2.4 | (1.1) |
| IL-15 | 1.6 | 2.9 | (1.4) |
| IL-9 | 1.3 | 2.3 | (1.0) |
| GROα (CXCL1) | 3.0 | 8.9 | (6.0) |
| IL-13 | 1.5 | 2.2 | (0.7) |
| IFN-γ | 1.1 | 2.1 | (1.0) |
a
In the pilot experiment, 50 immunomodulators were tested in a multiplex format. Patient groups with multiple antibodies (>3 antigens) and limited antibodies (≤3 antigens) are shown. Immunomodulator fold changes with respect to analyte assay baselines (see Materials and Methods) were determined by multivariate analysis. The difference between the two patient groups is also shown. Values in parentheses indicate negative fold changes.